total intravenous anesthesia tiva refers intravenous administration anesthetic agents induce temporary loss sensation awareness first study tiva done using chloral common anesthetic agent propofol licensed tiva currently employed various procedures alternative technique general anesthesia order improve postoperative recovery tiva maintained intravenous infusion devices assisted electroencephalography eeg monitoring techniques facilitate use propofol etomidate ketamine intravenous anesthetic agents tiva patients may subjected elevated risk anesthesia awareness hyperalgesia considering risks special consideration given obese elderly pediatric patientscitation needed century specific equipment developed enable intravenous anesthesia francis rynd developed hollow needle charles gabriel pravaz developed syringe allowed drugs administered intravenously using new mode delivery many chemical compounds tested intravenous anesthetics pioneered pierrecyprian ore reported using chloral hydrate intravenous however early trials associated high hedonal later developed general anesthesia although limited success due long duration insufficiencies encouraged development paraldehyde noel magnesium sulfate peck well ethanol intravenous anesthetic agents propofol diisopropyl phenol synthesized glen colleagues early first formulations temporarily withdrawn due number adverse reactions clinical lipid emulsion formulation propofol available carried great potential clinical licensed use europe received fda approval us propofol used worldwide welldefined pharmacological profile variety medical uses tiva used induce general anesthesia avoiding disadvantages volatile anesthesia traditional inhalation intravenous anesthetic agents titrated safe doses maintain stage iii surgical anesthesia unconsciousness amnesia immobility absence response noxious use tiva advantageous cases volatile anesthesia high risk impossible cases involving morbidly obese tiva also used anesthetic delivery sites trauma serious accidents disasters overall goals tiva propofolbased tiva significantly improves postoperative recovery profile comfort minimizes nausea vomiting facilitates rapid recovery greater hemodynamic stability preservation hypoxic pulmonary vasoconstriction reduction intracerebral pressure reduces risk organ despite advantages accounts small proportion general anesthetics due relatively expensive cost preparation doses intravenous sedativehypnotic adjuvant agents vary individually pharmacodynamic pharmacokinetic factors need considered patient eg patients impaired kidney liver function blood abnormalities myocardial dysfunction also risks adverse effects related doses hypotension respiratory terms adjuvant agents coadministration anesthetic drugs different classes often produce synergistic hypnotic especially common agents acting gammaaminobutyric acid gaba receptors combined drugs acting different types drug interactions sedativehypnotic agents adjuvant agents suggest dosing regimens instead dosing based adjusted body weight estimated lean body weight especially obese patients recommended drug doses titrated brief intervals around delivery intravenous anesthetics dependent different types infusion devices examples infusion devices include smart pumps syringe pumps targetcontrolled infusion tci smart pumps commonly used administer potent anesthetics various vasoactive drugs vasopressors inotropes vasodilators need continuously titrated operating smart pumps advantageous since administer safe doses programmed infusion rate within preexisting limits based institutional standardized medication syringe pumps smaller infusion pumps allow administration small amounts induction agents precise accuracy syringe pumps dependent selection syringes pump programming pumps able identify size syringe automatically syringe manufacturers name input targetcontrolled infusion tci systems assisted computer systems make use pharmacokinetic pharmacodynamic modelling maintain target concentration anesthetic tci requires clinicians input target concentration anesthetic agents computer calculate amount agent required input concentration infusion pump used deliver calculated bolus subsequently computer continuously recalculates much drug system influences amount drug required maintain desired concentration effect tiva continuous assessment heart rate blood pressure state consciousness essential titrating anesthetic processed electroencephalogram eeg monitoring used assess anesthetic however seconds lag time subjects state consciousness processed eeg signal limits usefulness induction propofol etomidate ketamine common intravenous sedativehypnotic agents induction highly lipophilic nature allows rapid onset anesthesia upon intravenous also enables penetration barrier effective perfusion brain however rapid redistribution agents brain muscle fat tissues causes short duration action adjuvant agents typically administered addition sedativehypnotic agents supplement induction propofol usually selected sedativehypnotic agent maintain general anesthesia tiva rapid onset offset beneficial properties adverse rapid onset action due high lipidsolubility rapid redistribution brain parts body rapid clearance propofol conjugated liver pharmacologically inactive although long terminal elimination halflife hours plasma concentrations remain low typical induction advantages include antiemetic antipruritic bronchodilatory anticonvulsant properties makes suitable patients kidney liver potential adverse effects propofol include hypotension respiratory depression caused inadequate dosing pain injection risk etomidate suitable patients hemodynamic instability since compromise blood pressure cardiac output heart advantages include anticonvulsant properties hemodynamic stability potential adverse effects include higher incidence postoperative nausea vomiting transient acute adrenal insufficiency pain injection involuntary myoclonic movements absence analgesic effects mild increases airway ketamine suitable hypotensive patients patients risks developing hypotension eg hypovolemia hemorrhage sepsis severe cardiovascular ketamine associated increased blood pressure heart rate cardiac advantages include profound analgesic properties bronchodilation ability maintain airway reflexes respiratory could also induced via intramuscular route tiva access gets lost however potential adverse effects impact cardiovascular neurological functions potential adverse effects cardiovascular activities listed potential adverse effects neurological activities listed opioid lidocaine midazolam adjuvant agents frequently administered minimize pain injection induction also used lessen sympathetic stress response cough reflex laryngoscopy intubation supplement sedation synergistic dose sedativehypnotic agents reduced due synergistic effects combined adjuvant choice specific adjuvant agents dependent upon patient procedurespecific opioid commonly administered adjuvant agent analgesic component tiva however used propofol might exacerbate adverse hypotensive potential adverse effects include respiratory depression bradycardia delirium potential acute patients tiva higher risk aaga unlike inhaled anesthetic agents intravenous agents indicative endtidal anesthetic concentration etac monitoring administered drugs determination successful delivery usually left anesthetists clinical high incidence aaga tiva attributed several factors firstly target concentration anesthetic agents required maintain unresponsiveness well although studies aiming establish target concentration propofol high degree variability established dosing secondly intravenous delivery may impaired lax monitoring intravenous catheter insertion thirdly use neuromuscular blockades risk factor aaga also hinders communication distress case accidental tiva techniques involve continued administration opioids eg remifentanil high doses cause opioidinduced may lead difficult postoperative pain control patients hyperalgesia experience increased chronic pain require analgesics following prolonged anesthetic exposure result death neural cells defective caused increased expression neurologically harmful resulting neurologic injuries may lead persistent subtle decline cognitive abilities especially elderly young animal studies suggest propofol may similar neurotoxic properties associated apoptotic degeneration obese patients present technical physiological challenges tiva physical tasks surgical positioning intravenous insertion ventilation complicated excess associated physiological pharmacological changes include higher susceptibility hypoxemia decrease resting metabolic rate lower cardiac output per kg body use dosing models derived nonobese patients therefore unsuitable obese even within obese population large variability individuals limits accuracy pharmacokinetic models predicting informing anesthetic infants differ adults consideration pharmacokinetics pharmacodynamics side terms pharmacokinetics protein binding organ function body composition significantly pharmacodynamic effects capacity target organs respond drugs also based knowledge doses adjusted achieve optimal clinical response avoid toxicity pediatric generally clearance drug elimination body greater children due nonlinear scaling body size aging associated increase fat reduction lean body mass total body factors increase volume distribution lipidsoluble drugs lower plasma concentration delay aged patients typically higher sensitivity drug action due reduction initial drug clearance resulting higher plasma concentration hence greater initial drug httpsenwikipediaorgwikitotalintravenousanaesthesia